BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 7, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» Seed funding at Resalis to support development of ncRNA-based therapeutics for metabolic disease
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Endocrine/Metabolic
Seed funding at Resalis to support development of ncRNA-based therapeutics for metabolic disease
Feb. 23, 2023
No Comments
Resalis Therapeutics Srl has completed a seed financing round of €10 million (US$10.6 million) to establish a noncoding RNA (ncRNA)-based...
BioWorld Science
Financings
Endocrine/metabolic
Antisense
Seed
